Reported about 6 hours ago
Allurion has launched a program to provide access to compounded weight-loss drugs, responding to the growing interest in GLP-1 drugs like Wegovy and Zepbound. This comes as the FDA aims to limit access to compounded versions following a declaration of no shortage of tirzepatide. The Allurion program incorporates AI to assist users with diet and exercise alongside the use of these compounded drugs, despite the company's own ingestible balloon device showing effectiveness in weight loss.
Source: YAHOO